Indonesia and Russia Explore Diabetes Drug Cooperation
The two nations are discussing pharmaceutical technology transfers to boost local production and lower import dependence.
Updated on Oct. 25, 2026 in Diabetes
Live Poll
Should the government prioritize domestic manufacturing to reduce the country's reliance on imported medicine?
Indonesia and Russia are working to finalize a memorandum of understanding to facilitate pharmaceutical technology transfers, specifically focusing on diabetes treatments. This collaboration aims to increase domestic medicine production in Indonesia while reducing its reliance on imports.
Why it matters
By sharing manufacturing expertise, Indonesia seeks to bolster its healthcare infrastructure and ensure more consistent public access to essential diabetes medications. The partnership formalizes a regulatory framework designed to streamline the approval process for international drug companies.
Russia's State Institute of Drugs and Good Practices has completed over 4,000 GMP inspections across 75 countries since 2016. Currently, the institute employs 58 qualified inspectors and offers 40 technical training modules through the Eurasian Academy.
The players
Food and Drug Authority (BPOM)
This is the Indonesian government agency responsible for overseeing the safety, efficacy, and quality of pharmaceutical products.
State Institute of Drugs and Good Practices (SID&GP)
This is a Russian regulatory body that conducts inspections to ensure compliance with pharmaceutical manufacturing standards.
Eurasian Academy of Good Practices
This organization provides technical training programs and professional development for regulatory inspectors.
The details
The collaboration involves exchanging Good Manufacturing Practice (GMP) information, training inspectors, and utilizing virtual reality simulations for training. As part of this initiative, Indonesia's Food and Drug Authority (BPOM) recently conducted a GMP inspection at an insulin manufacturing facility in Russia.
Timeline
Since 2016, SID&GP has conducted international GMP inspections.
Cooperation initiatives between BPOM and SID&GP launched in 2021.
BPOM performed a GMP inspection in Russia in May 2026.
Officials met in Jakarta on October 24, 2026, to discuss technology transfers.
The Big Picture
This initiative follows the global benchmarks established by the WHO Good Manufacturing Practices (GMP) standards to ensure rigorous drug quality control. The cooperation between Indonesia and Russia aligns with these international protocols to standardize pharmaceutical safety across borders.
This partnership aims to improve the long-term availability and affordability of insulin and other diabetes medications for patients in Indonesia. By increasing domestic production, the initiative hopes to insulate the local market from international supply chain disruptions.
The takeaway
Collaborations between national regulatory bodies can play a critical role in addressing regional health challenges by streamlining pharmaceutical imports. Patients can stay informed about medication supply stability by monitoring updates from their national health authorities.
Further reading
Learn more about global treatment initiatives on our Diabetes page.
Live Poll
Should the government prioritize domestic manufacturing to reduce the country's reliance on imported medicine?
